Trial Profile
Phase II Trial of Bortezomib and Rituximab for Patients With Post Transplant Lymphoproliferative Disorders (PTLD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary)
- Indications Lymphoproliferative disorders
- Focus Therapeutic Use
- 19 Feb 2016 Planned End Date changed from 1 April 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 12 Apr 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 12 Apr 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Sep 2011 as reported by ClinicalTrials.gov record.